Digital Angel Corporation (doc)

[RedneckInvestor]

November 30, 2007 - 8:33 AM EST

Digital Angel's Manufacturing Partner Raytheon Microelectronics Espana S.A. to Participate in Production Development of Self-Contained Implantable RFID Glucose-Sensing Microchip
Raytheon to Participate in Event on December 4 at Grand Hyatt in New York

Digital Angel Corporation ("Digital Angel") (AMEX:DOC), an advanced technology company in the field of rapid and accurate identification, location tracking and condition monitoring of high-value assets, and VeriChip Corporation (“VeriChip”) (NASDAQ:CHIP), a provider of RFID systems for healthcare and patient-related needs, announced today its manufacturing partner, Raytheon Microelectronics Espana S.A. will participate in the production development of a self-contained implantable RFID glucose-sensing microchip being developed by Digital Angel and its project partners VeriChip and RECEPTORS LLC.

Raytheon Sales Manager John Reddy will join Digital Angel, VeriChip and RECEPTORS for an event on December 4, 2007, at 4:30 p.m. EST at the Grand Hyatt in New York to unveil plans to build a prototype self-contained implantable bio-sensing device included in an RFID microchip that for the first time will have the ability to measure glucose levels in the human body, thereby negating the need for diabetics to prick their fingers multiple times per day. Dr. Manny Alvarez, Chairman of the Department of Obstetrics and Gynecology and Reproductive Science at Hackensack University Medical Center and FoxNews.com health managing editor, will also speak at the event.

Parties interested in attending the New York event should contact Allison Tomek at 561-805-8008 as soon as possible. Space is limited.

About RECEPTORS LLC

RECEPTORS' technology originates from its CARA(TM) AFFINITY BY DESIGN(TM) Discovery Platform, which allows the company to optimize artificial receptors to any application. Its product suite focuses on the development of an integrated proteomics "toolkit", with an emphasis on high-performance protein isolation and biomarker discovery. RECEPTORS LLC is privately held. For more information on RECEPTORS, please call 1-952-448-4337, or email [e-mail]. Additional information can be found online at http://www.receptorsllc.com.

About Digital Angel Corporation

Digital Angel Corporation (AMEX:DOC) is a leading provider of radio frequency identification (RFID) and global positioning system (GPS) technologies that enable the rapid and accurate identification, location tracking and condition monitoring of people, animals and high-value assets. The company’s products are utilized around the world in such applications as pet identification using its patented, FDA-approved implantable microchip; livestock identification and tracking using visual and RFID ear tags; and GPS search and rescue beacons for use on aircraft, ships and boats, and by adventure enthusiasts. Digital Angel Corporation has entered into an agreement to merge with its parent company Applied Digital Solutions, Inc. (NASDAQ:ADSX).

About VeriChip

VeriChip, headquartered in Delray Beach, Florida, develops, markets and sells radio frequency identification, or RFID, systems used to identify, locate and protect people and assets. VeriChip's goal is to become the leading provider of RFID systems for people in the healthcare industry. The Company recently began marketing its VeriMed(TM) Patient Identification System, a passive RFID system for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip, the implantable VeriChip(TM), cleared for medical use in October 2004 by the United States Food and Drug Administration.

VeriChip Corporation is majority-owned by Applied Digital Solutions, Inc. (NASDAQ:ADSX), which also owns a majority position in Digital Angel Corporation (AMEX:DOC). Digital Angel, a leader in RFID and GPS technologies, owns the patent on the human implantable, passive RFID microchip and manufactures it for VeriChip. For more information on VeriChip, please call 1-800-970-2447, or email [e-mail]. Additional information can be found online at www.verichipcorp.com.

This press release includes forward-looking statements, including but not limited to statements regarding the potential development, clinical trials and commercialization of an implantable glucose-sensing microchip, the potential of the microchip to revolutionize diabetes care and management and to negate the need for diabetics to draw blood to monitor blood glucose levels, its ability to painlessly and accurately scan, determine, and transmit glucose concentration levels to a wireless scanner, and the potential for it to operate properly within the human body for the timeframe intended. VeriChip and Digital Angel wish to caution readers that certain important factors and various risks may have affected and could in the future affect VeriChip's and Digital Angel's actual results and could cause VeriChip's and Digital Angel's actual results for subsequent periods to differ materially from those expressed in any forward-looking statement made by or on behalf of VeriChip and Digital Angel. With respect to VeriChip's and Digital Angel's expectations expressed in this press release, such risk factors include, but are not limited to, the performance of the product according to VeriChip's and Digital Angel's expectations. This information is also qualified in its entirety by cautionary statements and risk factor disclosures contained in VeriChip's and Digital Angel's Securities and Exchange Commission filings, including VeriChip's and Digital Angel's annual reports on Form 10-K for the fiscal year ended December 31, 2006 and its quarterly reports. VeriChip and Digital Angel can offer no assurances that any projections, assumptions or forecasts made or discussed in this release will be met, and investors should understand the risks of investing solely due to such projections. VeriChip and Digital Angel undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.


VeriChip and Digital Angel
Allison Tomek, 561-805-8008
or
CEOcast
Dan Schustack, 212-732-4300
or
RECEPTORS LLC
Kris Vanella, 952-448-4337




Source: Business Wire (November 30, 2007 - 8:33 AM EST)

News by QuoteMedia
www.quotemedia.com